Last update 04 Nov 2024

Tocilizumab-bavi

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Tocilizumab biosimilar (Bio-Thera Solutions), 重组人源化抗人白介素6受体单抗 (百奥泰生物), BAT-1806
+ [4]
Target
Mechanism
IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
EU
20 Jun 2024
COVID-19
IS
20 Jun 2024
COVID-19
LI
20 Jun 2024
COVID-19
NO
20 Jun 2024
Oligoarticular Arthritis
EU
20 Jun 2024
Oligoarticular Arthritis
IS
20 Jun 2024
Oligoarticular Arthritis
LI
20 Jun 2024
Oligoarticular Arthritis
NO
20 Jun 2024
Polyarticular Juvenile Idiopathic Arthritis
US
29 Sep 2023
Cytokine Release Syndrome
CN
16 Jan 2023
Rheumatoid Arthritis
CN
16 Jan 2023
Systemic onset juvenile chronic arthritis
CN
16 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Juvenile Idiopathic ArthritisNDA/BLA
US
09 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
621
TCZ
ohbtkjkpqh(gxhatujdtz) = qmapjjjttw scewoshnpi (cmtixjuhtf )
Positive
07 Sep 2024
TCZ to BAT1806/BIIB800
ohbtkjkpqh(gxhatujdtz) = vhqklplpyl scewoshnpi (cmtixjuhtf )
Phase 3
621
BAT1806
hrxiuabydt(funjnugtbo) = cdemqnlkws ahcfwfzinb (rlnmmsealx )
Similar
01 Jan 2024
hrxiuabydt(funjnugtbo) = hgnlemfzfn ahcfwfzinb (rlnmmsealx )
Phase 1
-
138
uotwgexzkm(viqutxltdc) = similar in all three groups: BAT1806 (n = 45), RoActemra-EU (n = 42), and Actemra-US (n = 42). The 90% confidence intervals (CIs) for the ratios of C max , AUC0-t and AUC0-∞ were 86.90-104.41% for BAT1806 vs. RoActemra-EU, 91.70-106.15% for BAT1806 vs Actemra-US, and 90.04-105.53% for Actemra-US vs RoActemra-EU. For all comparisons, the 90% CIs for the C max , AUC0-t , and AUC0-∞ were within the predefined bioequivalence limit of 80.00-125.00%. tfucylvshc (yenkzmcxpn )
Similar
01 Jan 2020
RoActemra-EU
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free